Myeloma

New technologies boost safety for patients with cancer who need donated blood.

Newer treatments for multiple myeloma come with an increased risk for thrombosis, but researchers discovered five factors that could help prevent the side effect.

CURE spoke with Ryan Anthony, a Dallas Symphony trumpet player, about how his passion for music led to his myeloma diagnosis and the start of his foundation CancerBlows.

From an FDA warning to real-life superheroes, here’s what is making headlines in the cancer space this week.

From today’s top performers and athletes to medical aid in dying, here’s what is making headlines in the cancer space this week.

Researchers examined what goes into treatment decision-making for patients with multiple myeloma.

The use of Darzalex in combination with Revlimid, Velcade and Ozurdex demonstrated a higher percentage of stringent complete responses among transplant eligible, newly diagnosed patients with multiple myeloma.

From today’s top performers and athletes to life-threatening social media disinformation, here’s what is making headlines in the cancer space this week.

The Food and Drug Administration has granted an accelerated approval to Xpovio in combination with dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received more than four prior therapies.

The FDA has approved the combination of Darzalex with Revlimid and dexamethasone (DRd) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

The Food and Drug Administration lifted a partial clinical hold on the CANOVA trial, examining Venclexta plus dexamethasone for some patients with relapsed/refractory myeloma.

In the second part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him about the past, present and future of the myeloma landscape.

In the first part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him on the current initiatives and resources available to patients.

Researchers determined that having difficulty performing at least one instrumental activity of daily living puts older patients at risk of death, unplanned hospitalization and emergency department visits.

The Food and Drug Administration granted a priority review to Darzalex in combination with Velcade (bortezomib), thalidomide and dexamethasone, also known as Vtd, for the front-line treatment of newly diagnosed patients with multiple myeloma.

The FDA has approved Jakafi, the first and only treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients aged 12 years and older.

From World Blood Cancer Day to today’s top performers fundraising for lifesaving research, here’s what’s making headlines in the cancer space this week.

Using Revlimid as a preventative treatment for smoldering multiple myeloma significantly reduced the risk for the precursor disease to progress into cancer, compared with just observation.

Treatment with bb2121 showed promising efficacy and safety among heavily pretreated patients with multiple myeloma, according to interim results published in the New England Journal of Medicine.

Only half of patients reported their blood cancer was detected while visiting a doctor after experiencing symptoms versus detection during a routine medical test or exam or while under the care of a doctor for another health condition.

An expert discusses how CAR-T cells will fit into the treatment paradigm for patients with multiple myeloma in the future.

Although a reasonable and often curative treatment option, use of allogeneic hematopoietic stem cell therapy in relapsed multiple myeloma still tends to fall under the radar.

An expert discusses treating multiple myeloma with potential curative intent.

The Oncologic Drugs Advisory Committee (ODAC) voted 8 to 5 recommending the FDA delay approval of selinexor for the treatment of patients with penta-refractory multiple myeloma until further trial data are available.

Outcomes associated with subcutaneous injections of Darzalex (daratumumab) appeared similar to IV administration in patients with relapsed or refractory myeloma, according to the phase 3 COLUMBA trial.

Patients with multiple myeloma find relief from side effects, thanks to newer drug combinations.

Researchers are using innovative technology to hunt down hidden cancer cells.

The Food and Drug Administration (FDA) approved a split-dosing regimen for Darzalex (daratumumab) for the treatment of patients with multiple myeloma.

Obesity may be to blame for increasing rates of certain cancers in young adults.

Splitting up Darzalex dosing had comparable results to standard dosing schedules in patients with myeloma.